Federal Register / Vol. 69, No. 191 / Monday, October 4, 2004 / Notices 59261

Dated: September 27, 2004. 

Tina M. Cheatham, 

Director, Division of Policy Review and 

Coordination.

[FR Doc. 04–22184 Filed 10–1–04; 8:45 am] 

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing

AGENCY: National Institutes of Health, 

Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing.

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Chromatography Apparatus and 

Method 

Yoichiro Ito (NHLBI) 

U.S. Provisional Application Filed 24 

Aug 2004 (DHHS Reference No. E–

277–2004/0–US–01) 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing for industrial 

scale-up production and commercial 

distribution is an improved 

countercurrent chromatography 

apparatus comprising a disk having a 

series of interconnected and elongated 

compartments coupled by ducts that 

form a portion of a groove in a surface 

of the disk. At least some of the 

elongated compartments have an aspect 

ratio of at least greater than two and a 

width greater than twice the width of 

the connecting ducts and a length of 

about 10 to 20 times the length of the 

connecting ducts. This apparatus may 

also be used for a large-scale industrial 

separation by coaxially rotating in 

centrifugal or gravitational fields.

HIV–1 Infection Detection Assay for 

Seroconverted HIV–1 Vaccine 

Recipients 

Hana Golding, Surender Khurana (FDA/

CBER) 

U.S. Provisional Application Filed 08 

Sep 2004 (DHHS Reference No. E–

259–2004/0–US–01) 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing and 

commercial distribution is an assay 

method and kit having diagnostic 

peptide fragments derived from human 

immunodeficiency virus-1 (HIV–1). The 

new serology assay includes HIV–1 

peptide fragments epitopes that map to 

HIV–1 GAG–p6, and gp41 genes. These 

epitopes are broadly reactive with early 

sera from HIV infected individuals, do 

not illicit protective antibodies, do not 

illicit immunologic cytotoxicity and are 

readily removable from current and 

future HIV–1 candidates. The assay is 

advantageous in detecting HIV–1 early 

breakthrough infections in 

seroconverted vaccine recipients while 

being able to distinguish between 

individuals with bonafide breakthrough 

infections versus non-HIV infected 

vaccine recipients presenting only 

vaccine borne antibodies. For example, 

90% of vaccine recipients receiving a 

Canarypox construct expressing a 

plurality of HIV antigens (Env, Gag, Pol, 

HIV Protease, Nef) followed by an 

envelope protein boost, scored positive 

in FDA licensed enzyme immunoassay, 

rapid test, and Western blot (MartaLouise Ackers et al., J Infect Dis. 

187:879 (2003)). Such seroconversion 

has a negative impact on phase III 

efficacy trials of prophylactic HIV 

vaccines that require early detection of 

breakthrough infections and also 

exclude non-HIV infected vaccine 

recipients from the pool of potential 

blood donors.

Flow-Through, Thermal-ExpansionCompensated Microcells for Analytical 

Transmission Infrared and Other Light 

Spectroscopies 

Edward Mertz (NICHD), James Sullivan 

(ORS) 


EN04OC04.040</GPH>
59262 Federal Register / Vol. 69, No. 191 / Monday, October 4, 2004 / Notices 

U.S. Patent Application No. 10/926,405 

Filed 26 Aug 2004 (DHHS Reference 

No. E–096–2004/0–US–01) 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing and 

commercial distribution are optical cells 

that are spectroscopically, thermally 

and mechanically stable and can be 

used for spectroscopic measurement in 

transmission, reflection, transmissionreflection, emission, or scattering modes 

without modification of standard 

spectrometers. The cell handles liquid 

samples and biological or solid samples 

equilibrated with bathing fluid which 

does not interfere with the light beam, 

allows liquid sample or bathing fluid to 

be exchanged without cell reassembly, 

requires only a small amount of sample 

(down to 0.1μl), allows for different 

sample gaps (0.2–1000μm) to be easily 

and inexpensively set, and allows 

spectral measurements to be taken over 

wavelengths ranging at least from the 

mid-infrared to the vacuum ultraviolet. 

The inventive cell and methods allows 

sensitive and reproducible monitoring 

spectra and their changes (down to at 

least 10¥4 absorbance units) caused by 

changes in temperature or in 

composition of bathing fluid or by fast 

kinetic processes. 

This research is described, in part, in 

Mertz E.L., Leikin S. ‘‘Interactions of 

Inorganic Phosphate and Sulfate Anions 

with Collagen’’, Biochemistry, in press. 

Device for Sequential Protein Transfer 

From a Gel 

Jozsef Antal, Zsuzsanna Buzas, Andreas 

Chrambach (NICHD) 

DHHS Reference No. E–346–2003/0–

US–01 filed 09 July 2004 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing and 

commercialization is a device for 

sequentially eluting proteins and 

peptides. The device comprises a 

separation medium having an outlet, 

and a collector having a first receptacle 

and second receptacle that can be 

sequentially brought into contact with 

the outlet of the separation medium by 

translating (rotating) the first receptacle 

and the second receptacle in relation to 

the outlet of the separation medium. 

The invention is adaptable to capillary 

electrophoresis as well. Multiple 

sequential protein transfer from SDS–

PAGE gel to a mass spectrometer is 

made possible. Separated protein bands 

sequentially electrophorese into low 

melting agarose plugs distributed along 

the surface of a plastic drum. The 

effective electroelution of a protein from 

a gel band to an agarose filled slot. The 

drum is rotated to receive each band 

individually. Migrating SDS linearized 

proteins are electrophoresed into the 

receptacle slot drum. The drum is rolled 

until each protein of interest is 

separated. Agarose plugs are lifted from 

the drum slots; enzymatically dissolved, 

and loaded directly onto a MALDI 

spectrometer. Between two agarose 

layers, gel free collection chambers can 

be formed inside the drum providing 

solution phase fraction collection.

This research is described in: Buzas Z, 

Antal J, Gilligan JJ, Backlund PS, Yergey 

AL, Chrambach A. An electroelution 

apparatus for sequential transfer of 

sodium dodecyl sulfate-proteins into 

agarose and mass spectrometric 

identification of Li-Na-dodecyl sulfateproteins from solubilized agarose. 

Electrophoresis. 2004 Apr;25(7–8):966–

9. 

Simultaneous HDL/LDL/Total 

Lipoprotein Single Tube Homogeneous 

Assay 

Alan T. Remaley, Maureen Sampson, 

Gyorgy Csako (CC) 

DHHS Reference No. E–090–1999: U.S. 

Patent App. 09/980,751 Filed 01 Nov 

2001; European Patent App. Ser. No. 

00939404.0 Filed 26 May 2000; 

Canadian Patent. App. 2375210 Filed 

26 May 2000; Australian Pat. App. 

54493/00 filed 26 May 2000; Japanese 

Patent App. 2001–500866 filed 26 

May 2000 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing is an invention 

in which a single tube assay is used for 

determining high-density lipoprotein 

HDL-cholesterol (HDL–C), low density 

lipoprotein (LDL–C) and total 

cholesterol (total-C), from a single serum 

sample. This assay is an efficient tool 

for use in determining patient risk 

factors for heart disease. Previously, 

multiple costly tests were performed in 

order to determine low-density 

lipoprotein LDL–C and HDL–C by 

measuring total-C, total triglyceride, and 

HDL–C. That method of testing had 

limitations and was complex. Using this 

methodology, the homogeneous assay 

for HDL–C does not require physically 

separating HDL. The new assay 

developed is efficient, less costly, and 

compares favorably to current assays for 

HDL–C, total cholesterol, and 

triglyceride. This technology may also 

be used to simplify the procedure for 

the point of care testing of 

hyperlipidemia.

Dated: September 22, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–22151 Filed 10–1–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Center for Substance Abuse 

Prevention Correction of Meeting 

Notice 

Pursuant to Pub. L. 92–463, notice is 

hereby given of a correction of a notice 

of a meeting of the Substance Abuse 

Prevention (CSAP) National Advisory 

Council to be held in October 2004. 

Public notice was given in the Federal 

Register on September 27, 2004 

(Volume 69, Number 186, page 57711) 

that the CSAP National Advisory 

Council would be meeting on October 5 

and 6, 2004 at The Times Building, One 

Times Square, Third Floor, New York, 

New York. The place for this meeting 

has subsequently changed to The 

Renaissance New York Hotel Times 

Square, Two Times Square, 714 Seventh 

Avenue at W. 48th Street, New York, 

New York. The agenda and date of the 

meeting and contact for additional 

information remain as announced.

Dated: September 30, 2004. 

Toian Vaughn, 

SAMHSA Committee Management Officer, 

Substance Abuse and Mental Health Services 

Administration.

[FR Doc. 04–22339 Filed 10–1–04; 8:45 am] 

BILLING CODE 4162–20–P


EN04OC04.041</GPH>